Exploring Why We Need to Mine the Dark Genome to Find the Targets for Affordable Multi-valent Immunotherapies
9:00 am - Thursday 23rd July 2026
- Exploring the limitations of conventional neoantigens including immune escape and restricted patient coverage
- How aberrantly expressed TSAs represent an untapped source of highly tumour specific targets that may evade central tolerance
- Demonstration of the potential of dark genome antigens for tumour control in mice & modelling performance of multi-valent off-the-shelf cancer vaccines in patients
